Trial intelligence / Profile preview

Immunogenicity and Safety of AVAXIM 80U Pediatric vs HAVRIX 720 in Chinese Children and Adolescents

2015-005191-18Phase 3

Sponsor
Sanofi
Start
Nov 2015
Modality
Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
Countries
1
01

Overview

Phase 3, randomised trial of Avaxim Junior in hepatitis A (HAV) (2 arms), sponsored by Sanofi.

02

Drugs

Avaxim Junior
03

Conditions

hepatitis A (HAV)

Beyond the preview

Go deeper on 2015-005191-18.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2015-005191-18.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call